Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
October 18, 2017
Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017
October 18, 2017
Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
September 19, 2017
Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference
September 6, 2017
Revance Appoints Mark Foley to its Board of Directors
August 30, 2017
Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference
August 3, 2017
Revance Releases Second Quarter 2017 Results
August 2, 2017
Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics
July 24, 2017
Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017
June 15, 2017
Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery
June 5, 2017
Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial
Displaying 171 - 180 of 280